1199 related articles for article (PubMed ID: 2824710)
21. Alternating chemotherapy with cyclophosphamide, doxorubicin, vincristine and cisplatin, etoposide followed by prophylactic cranial and thoracic irradiation for small cell lung cancer (SCLC): long-term results.
Ardizzoni A; Fusco V; Pennucci C; Baldini E; Orsatti M; Vitale V; Bonavia M; Baracco F; Mereu C; Rosso R
Anticancer Res; 1991; 11(2):681-4. PubMed ID: 1648333
[TBL] [Abstract][Full Text] [Related]
22. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer.
Fukuoka M; Furuse K; Saijo N; Nishiwaki Y; Ikegami H; Tamura T; Shimoyama M; Suemasu K
J Natl Cancer Inst; 1991 Jun; 83(12):855-61. PubMed ID: 1648142
[TBL] [Abstract][Full Text] [Related]
23. Experience with ifosfamide and etoposide combination chemotherapy in extensive-disease small-cell lung cancer.
Wu MF; Perng RP; Chen YM; Liu JM; Yang SL; Whang-Peng J
Zhonghua Yi Xue Za Zhi (Taipei); 1997 Aug; 60(2):67-73. PubMed ID: 9360330
[TBL] [Abstract][Full Text] [Related]
24. Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer.
Einhorn LH; Crawford J; Birch R; Omura G; Johnson DH; Greco FA
J Clin Oncol; 1988 Mar; 6(3):451-6. PubMed ID: 2832549
[TBL] [Abstract][Full Text] [Related]
25. Ifosfamide, carboplatin, and etoposide with midcycle vincristine versus standard chemotherapy in patients with small-cell lung cancer and good performance status: clinical and quality-of-life results of the British Medical Research Council multicenter randomized LU21 trial.
Thatcher N; Qian W; Clark PI; Hopwood P; Sambrook RJ; Owens R; Stephens RJ; Girling DJ
J Clin Oncol; 2005 Nov; 23(33):8371-9. PubMed ID: 16293867
[TBL] [Abstract][Full Text] [Related]
26. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer.
Ihde DC; Mulshine JL; Kramer BS; Steinberg SM; Linnoila RI; Gazdar AF; Edison M; Phelps RM; Lesar M; Phares JC
J Clin Oncol; 1994 Oct; 12(10):2022-34. PubMed ID: 7931470
[TBL] [Abstract][Full Text] [Related]
27. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study.
Loehrer PJ; Ansari R; Gonin R; Monaco F; Fisher W; Sandler A; Einhorn LH
J Clin Oncol; 1995 Oct; 13(10):2594-9. PubMed ID: 7595712
[TBL] [Abstract][Full Text] [Related]
28. Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung.
Feld R; Evans WK; Coy P; Hodson I; MacDonald AS; Osoba D; Payne D; Shelley W; Pater JL
J Clin Oncol; 1987 Sep; 5(9):1401-9. PubMed ID: 3040923
[TBL] [Abstract][Full Text] [Related]
29. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine.
Johnson BE; Bridges JD; Sobczeck M; Gray J; Linnoila RI; Gazdar AF; Hankins L; Steinberg SM; Edison M; Frame JN; Pass H; Nesbitt J; Holden D; Mulshine JL; Glatstein E; Ihde DC
J Clin Oncol; 1996 Mar; 14(3):806-13. PubMed ID: 8622028
[TBL] [Abstract][Full Text] [Related]
30. Chemotherapy of small-cell carcinoma of lung: a randomized comparison of alternating and sequential combination chemotherapy programs.
Daniels JR; Chak LY; Sikic BI; Lockbaum P; Kohler M; Carter SK; Reynolds R; Bohnen R; Gandara D; Yu J
J Clin Oncol; 1984 Nov; 2(11):1192-9. PubMed ID: 6092554
[TBL] [Abstract][Full Text] [Related]
31. A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive-stage small-cell lung cancer: a phase III study of the Eastern Cooperative Oncology Group.
Ettinger DS; Finkelstein DM; Abeloff MD; Ruckdeschel JC; Aisner SC; Eggleston JC
J Clin Oncol; 1990 Feb; 8(2):230-40. PubMed ID: 2153765
[TBL] [Abstract][Full Text] [Related]
32. Multimodal therapy for limited small-cell lung cancer: a randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders: a Southwest Oncology Group Study.
Kies MS; Mira JG; Crowley JJ; Chen TT; Pazdur R; Grozea PN; Rivkin SE; Coltman CA; Ward JH; Livingston RB
J Clin Oncol; 1987 Apr; 5(4):592-600. PubMed ID: 3031226
[TBL] [Abstract][Full Text] [Related]
33. A phase III comparison of etoposide/cisplatin with or without added ifosfamide in small-cell lung cancer.
Miyamoto H; Nakabayashi T; Isobe H; Akita H; Kawakami Y; Arimoto T; Asakawa M; Suzuki A; Fujikane T; Shimizu T
Oncology; 1992; 49(6):431-5. PubMed ID: 1334539
[TBL] [Abstract][Full Text] [Related]
34. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group.
Murray N; Livingston RB; Shepherd FA; James K; Zee B; Langleben A; Kraut M; Bearden J; Goodwin JW; Grafton C; Turrisi A; Walde D; Croft H; Osoba D; Ottaway J; Gandara D
J Clin Oncol; 1999 Aug; 17(8):2300-8. PubMed ID: 10561291
[TBL] [Abstract][Full Text] [Related]
35. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.
Hanna N; Bunn PA; Langer C; Einhorn L; Guthrie T; Beck T; Ansari R; Ellis P; Byrne M; Morrison M; Hariharan S; Wang B; Sandler A
J Clin Oncol; 2006 May; 24(13):2038-43. PubMed ID: 16648503
[TBL] [Abstract][Full Text] [Related]
36. Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma.
Glisson B; Lee JS; Palmer J; Fossella F; Shin DM; Murphy WK; Perez-Soler R; Hong WK
Cancer; 1998 Jan; 82(2):301-8. PubMed ID: 9445186
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
Han JY; Cho KH; Lee DH; Kim HY; Kim EA; Lee SY; Lee JS
J Clin Oncol; 2005 May; 23(15):3488-94. PubMed ID: 15908658
[TBL] [Abstract][Full Text] [Related]
38. The use of VP-16 plus cisplatin during induction chemotherapy for small-cell lung cancer.
Evans WK; Feld R; Murray N; Pater J; Shelley W; Willan A; Osoba D; Levitt M; Coy P; Hodson I
Semin Oncol; 1986 Sep; 13(3 Suppl 3):10-6. PubMed ID: 3020692
[TBL] [Abstract][Full Text] [Related]
39. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.
Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Hatlevoll R; Dahle R; Boye N; Wang M; Vigander T; Vilsvik J; Skovlund E; Hannisdal E; Aamdal S;
J Clin Oncol; 2002 Dec; 20(24):4665-72. PubMed ID: 12488411
[TBL] [Abstract][Full Text] [Related]
40. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer.
Mavroudis D; Papadakis E; Veslemes M; Tsiafaki X; Stavrakakis J; Kouroussis C; Kakolyris S; Bania E; Jordanoglou J; Agelidou M; Vlachonicolis J; Georgoulias V;
Ann Oncol; 2001 Apr; 12(4):463-70. PubMed ID: 11398877
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]